- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02839850
14022 ATTUNE Avaliação de desempenho clínico sem cimento RP
Avaliação Clínica Multicêntrica da Artroplastia Total de Joelho com Plataforma Rotativa Não Cimentada ATTUNE
The primary objective of this study is to examine the change from pre-operative baseline to two year postoperative functional performance improvement for the ATTUNE primary, cementless TKA RP system as measured with the KOOS questionnaire (KOOS-ADL sub-score). This will be carried out for two configurations: cruciate retaining rotating platform (ATTUNE Cementless CR RP) and posterior stabilized rotating platform (ATTUNE Cementless PS RP).
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The secondary objectives of this study are:
- Evaluate change from preoperative baseline in post-operative outcomes using additional patient reported measures at 2 years: PKIP (overall and sub-scores), KOOS (overall and sub-scores), AKS and EQ-5D-3L.
- Evaluate change from preoperative baseline in pain and satisfaction over time as measured using a modified VAS Pain Score (discrete numbers rather than a continual scale) at 2yr.
- Evaluate type and frequency of Adverse Events
- Evaluate survivorship of the ATTUNE Primary Cementless TKA system for the CR RP and PS RP configurations using Kaplan-Meier survival analysis at 2yr and 5yrs.
- Evaluate primary, cementless ATTUNE TKA fixation through zonal radiographic analysis of the bone-implant interface at 6wk, 6mo, 1yr, and 2yr after surgery.
- Evaluate any changes in anatomic tibiofemoral, femoral component and tibial component alignment at 2 years compared to the first postoperative radiographs.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Garmisch-Partenkirchen, Alemanha, 82467
- Klinikum Garmisch-Partenkirchen GmbH
-
-
-
-
Alberta
-
Calgary, Alberta, Canadá, T2N 2T9
- Foothills Medical Centre, University of Calgary
-
-
-
-
Colorado
-
Denver, Colorado, Estados Unidos, 80210
- Colorado Joint Replacement
-
-
Florida
-
DeLand, Florida, Estados Unidos, 32720
- Florida Research Associates
-
-
New Hampshire
-
Lebanon, New Hampshire, Estados Unidos, 03756
- Dartmouth-Hitchcock Medical Center
-
New London, New Hampshire, Estados Unidos, 03257
- New London Hospital
-
-
New Jersey
-
Egg Harbor, New Jersey, Estados Unidos, 08234
- Rothman Institute
-
-
New York
-
Brooklyn, New York, Estados Unidos, 11203
- SUNY downstate Medical Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27599
- UNC Chapel Hill
-
-
Tennessee
-
Kingsport, Tennessee, Estados Unidos, 37660
- Associated Orthopaedics of Kingsport
-
-
Texas
-
Lubbock, Texas, Estados Unidos, 49416
- Texas Tech University Heath Science Center
-
-
Virginia
-
Newport News, Virginia, Estados Unidos, 23606
- Hampton Roads Orthopaedics and Sports Medicine
-
-
-
-
-
Salouël, França, 80480
- Sevice de Chirurgie Orthoedique et Traumatologique
-
-
Cedex
-
Brest, Cedex, França, 29285
- CHU de la Cavale Blanche
-
-
-
-
North Brabant
-
Helmond, North Brabant, Holanda, 5707 HA
- Elkerliek Ziekenhuis
-
-
-
-
-
Cork, Irlanda, T12 X23H
- South Infirmary Victoria University Hospital
-
-
-
-
-
Christchurch, Nova Zelândia, 8083
- University of Otago
-
-
-
-
-
Nottingham, Reino Unido, NG5 1PB
- Nottingham University Hospitals NHS Trust
-
-
Lancashire
-
Wigan, Lancashire, Reino Unido, WN6 9EP
- Wrightington Hospital
-
-
-
-
Upper Austria
-
Ried im Innkreis, Upper Austria, Áustria, 4910
- Krankenhaus der Barmherzigen Schwestern Ried im Innkreis
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Subject is male or female and between the ages of 22 and 80 years at the time of surgery, inclusive.
- Subject was diagnosed with NIDJD.
- Subject, in the opinion of the Investigator, is a suitable candidate for cementless primary TKA using the devices described in this CIP with either resurfaced or non-resurfaced patellae.
- Subject that is willing to give voluntary, written informed consent to participate in this clinical investigation and authorize the transfer of his/her information to the Sponsor
- Subject is currently not bedridden
- Subject, in the opinion of the Investigator, is able to understand this clinical investigation and is willing and able to perform all study procedures and follow-up visits and co-operate with investigational procedures.
- Subject is able to read, and comprehend the Informed Consent Document as well as complete the required PROs in either English or one of the available translations.
Exclusion Criteria:
- The Subject is a woman who is pregnant or lactating.
- Contralateral knee has already been enrolled in this study .
- Subject had a contralateral amputation.
- Previous partial knee replacement (unicompartmental, bicompartmental or patellofemoral joint replacement), patellectomy, high tibial osteotomy or primary TKA in affected knee.
- Subject is currently diagnosed with radicular pain from the spine that radiates into the limb to receive TKA.
- Subject has participated in a clinical investigation with an investigational product (drug or device) in the last three (3) months.
- Subject is currently involved in any personal injury litigation, medical-legal or worker's compensation claims.
- Subject, in the opinion of the Investigator, is a drug or alcohol abuser (in the last 5 years) or has a psychological disorder that could affect their ability to complete patient reported questionnaires or be compliant with follow-up requirements.
- Subject was diagnosed and is taking prescription medications to treat a muscular disorder that limits mobility due to severe stiffness and pain such as fibromyalgia or polymyalgia.
- Subject has a significant neurological or musculoskeletal disorder(s) or disease that may adversely affect gait or weight bearing (e.g., muscular dystrophy, multiple sclerosis, Charcot disease).
- Subject is suffering from inflammatory arthritis (e.g., rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, etc.).
- Subject has a medical condition with less than five (5) years life expectancy.
- Uncontrolled gout
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: ATTUNE Cementless RP TKA
Subjects will receive a cementless, rotating platform total knee arthroplasty |
Patients will undergo a primary total knee replacement using one of the two configurations of the ATTUNE Cementless knee (CR RP or PS RP) |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Patient-reported Outcome: Knee Injury and Osteoarthritis Outcome Score Activities of Daily Living (KOOS ADL)
Prazo: Minimum 2 years (670-1033 days after surgery)
|
The Knee injury and Osteoarthritis Outcome Score (KOOS) is a patient self-administered questionnaire that consists of 42 questions and include the WOMAC Osteoarthritis index. The KOOS consists of 5 subscales: pain, other symptoms, activities of daily living (ADL), sport and recreational function and knee related quality of life. Each question has 5 Likert-like response options. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated for each subscale. |
Minimum 2 years (670-1033 days after surgery)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Patient-reported Outcome: Pre-surgical/Post-surgical Patient's Knee Implant Performance (PKIP)
Prazo: Minimum 2 years (670-1033 days after surgery)
|
The Pre Surgical and/or Post-surgical Patient's Knee Implant Performance (PKIP) questionnaire is a patient self-administered questionnaire that consists of 25 questions relating to the patient's awareness of their knee. Questions include the patient's self-confidence about the current status of their knee performance, stability, and overall satisfaction. Each question has a 5, 6 or 10 Likert- like response option. |
Minimum 2 years (670-1033 days after surgery)
|
|
Patient-reported Outcome: Knee Injury and Osteoarthritis Outcome Score (KOOS)
Prazo: Minimum 2 years (670-1033 days after surgery)
|
The Knee injury and Osteoarthritis Outcome Score (KOOS) is a patient self-administered questionnaire that consists of 42 questions and include the WOMAC Osteoarthritis index. The KOOS consists of 5 subscales: pain, other symptoms, activities of daily living (ADL), sport and recreational function and knee related quality of life. Each question has 5 Likert-like response options. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated for each subscale. |
Minimum 2 years (670-1033 days after surgery)
|
|
Combination of Patient-reported and Clinical-reported Outcome: Knee Society 2011
Prazo: Minimum 2 years (670-1033 days after surgery)
|
The Knee Society Score is a self-administered questionnaire. The subject completes questions regarding: Symptoms (3 questions), Patient Satisfaction (5 questions), Patient Expectations (3 questions), Functional Activities (5 questions), Standard Activities (6 questions), Advanced Activities (5 questions), and Discretionary Knee Activities ( 4 questions). The surgeon completes questions regarding objective knee indicators. Likert responses are used, typically with five response options. |
Minimum 2 years (670-1033 days after surgery)
|
|
Patient Reported Outcome: EuroQol 5D 3L questionnaire (EQ-5D-3L)
Prazo: Minimum 2 years (670-1033 days after surgery)
|
EuroQol 5D 3L questionnaire is a standardized instrument for use as a measure of health outcome that is designed for completion by the subject. |
Minimum 2 years (670-1033 days after surgery)
|
|
Modified VAS Pain Score: Pain and Satisfaction
Prazo: Minimum 2 years (670-1033 days after surgery)
|
VAS Pain Score is a standardized instrument for use as a measure of pain and satisfaction that is designed for completion by the subject. This modified version has scores that are discrete numbers rather than a continual scale |
Minimum 2 years (670-1033 days after surgery)
|
|
Type and Frequency of Adverse Events (AEs) for all enrolled subjects
Prazo: Pre-op (-90 to -1 days before surgery), 6 weeks (1-90 days after surgery), 6 months (91-303 days after surgery), minimum 1 year (304-669 days after surgery), minimum 2 years (670-1033 days after surgery), minimum 5 years (1764-2190 days after surgery)
|
All Serious AEs must be reported to Sponsor. All device-related or procedure-related adverse events must be reported to Sponsor. |
Pre-op (-90 to -1 days before surgery), 6 weeks (1-90 days after surgery), 6 months (91-303 days after surgery), minimum 1 year (304-669 days after surgery), minimum 2 years (670-1033 days after surgery), minimum 5 years (1764-2190 days after surgery)
|
|
Survivorship
Prazo: Minimum 2 years (670-1033 days after surgery)
|
Kaplan-Meier survival analysis will be used to calculate the survivorship of all 2 configurations (CR RP, PS RP) |
Minimum 2 years (670-1033 days after surgery)
|
|
Survivorship
Prazo: Minimum 5 years (1764-2190 days after surgery)
|
Kaplan-Meier survival analysis will be used to calculate the survivorship of all 2 configurations (CR RP, PS RP) |
Minimum 5 years (1764-2190 days after surgery)
|
|
Implant fixation: Radiographic assessment of bone-implant interface performance
Prazo: 6 weeks (1-90 days after surgery)
|
Radiographic success is defined as: absence of progressive radiolucent lines greater than or equal to 2mm in any one zone; absence of lytic lesions in any zone; absence of individual component position change >3degrees in any plane. |
6 weeks (1-90 days after surgery)
|
|
Implant fixation: Radiographic assessment of bone-implant interface performance
Prazo: 6 months (91-303 days after surgery)
|
Radiographic success is defined as: absence of progressive radiolucent lines greater than or equal to 2mm in any one zone; absence of lytic lesions in any zone; absence of individual component position change >3degrees in any plane. |
6 months (91-303 days after surgery)
|
|
Implant fixation: Radiographic assessment of bone-implant interface performance
Prazo: Minimum 1 year (304-669 days after surgery).
|
Radiographic success is defined as: absence of progressive radiolucent lines greater than or equal to 2mm in any one zone; absence of lytic lesions in any zone; absence of individual component position change >3degrees in any plane. |
Minimum 1 year (304-669 days after surgery).
|
|
Implant fixation: Radiographic assessment of bone-implant interface performance
Prazo: Minimum 2 years (670-1033 days after surgery)
|
Radiographic success is defined as: absence of progressive radiolucent lines greater than or equal to 2mm in any one zone; absence of lytic lesions in any zone; absence of individual component position change >3degrees in any plane. |
Minimum 2 years (670-1033 days after surgery)
|
|
Evaluate changes in femoral component and tibial component alignment
Prazo: Minimum 2 years (670-1033 days after surgery)
|
Radiographs will be reviewed by an independent radiographic reviewer (IRR) in order to minimize bias of radiographic outcomes. Data from the IRR radiographic evaluations will be used to evaluate femoral and tibial component alignment over time. |
Minimum 2 years (670-1033 days after surgery)
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Sukhjeet Kaur, Sponsor GmbH
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimado)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 14022
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .